2025 Q4 -tulosraportti
Vain PDF
77 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·23 min sittenThese are incredibly exciting opportunities. The Circio and Tcelltech collaboration aims to cure cancer that has entrenched itself with a single injection. When cancer has spread to multiple organs, we face a massive problem. To cure patients at this stage, we must program their immune cells to perform several demanding tasks simultaneously. Firstly, the immune cells must be able to track down tumors wherever they hide in the body. Secondly, they must be able to break down the hard, physical connective tissue that solid tumors build around themselves. And thirdly, they must be able to survive the toxic environment inside the tumor, which normally deactivates the body's own defenses. To program immune cells to do all this, we must introduce large amounts of genetic code into them. And here we hit a wall with today's technology: The standard is to use viruses to deliver the genes. But viruses are small. They have strict physical limitations and simply do not have room for the amount of genetic code required to tackle disseminated, solid cancer. This is what the collaboration between Circio and Tcelltech is now solving, so that treatment can occur directly inside the patient's body. Room for everything that is needed The solution starts with Tcelltech's technology, NanoSMAR. Since this is a synthetic DNA carrier that does not use viruses, it has extreme loading capacity. It removes the space problem. With NanoSMAR, researchers can package the entire genetic recipe in one and the same delivery: Both the instructions for tracking the cancer, the enzymes for breaking down the tumor's outer barriers, and the genes that keep the immune cell active. The treatment lasts until the job is done Once all these genes have been safely delivered into the cell, the next problem arises: Removing disseminated cancer takes time. Common gene recipes are quickly broken down in the body, and then the treatment burns out before all cancer cells are removed. This is where Circio's technology, circVec, comes in. They use circular RNA. Because the RNA is shaped like a closed ring without ends, the body's enzymes cannot break it down. This means that the immune cells continue to produce the necessary substances for several months. What this means in practice In short: NanoSMAR provides the space we need to deliver complex instructions, and circVec ensures that the instructions work for a long time. This gives us a concrete tool to give the patient a single injection. Subsequently, the body's own, upgraded immune cells will systematically hunt down and break down the cancer cells over several months, until the disease is gone. This is the technical foundation required to actually cure forms of cancer that are currently considered incurable.
·57 min sittenCompletely without news from Circio, one must well say that the alpine landscape of a graph (1d) we see above us, represents all those who try to earn some kroner on ups and downs. After a short year of trading on the stock exchange, what scares me is how easy it must be for a group of, for example, 4 people with 30 000 shares each, to influence the price. Concerted purchases start with many small and medium-sized positions, likewise sales. but there are surely control functions.....
Well, there's no volume anyway. People are waiting for data. The big investors with the money, who are not in yet, are doing the same.
·1 t sittenHave learned one thing today. DO NOT WAKE @vidfar who is sleeping!!
·1 t sittenThe reason is: * Circio Holding is still a biotech company without established commercial earnings. Its value largely depends on research, partnerships, and potential licensing agreements. * The freshest independent analysis I find has a base case of around 5.9 kroner per share, even after strong research results and new financing. * At the same time, biotech is known for large price jumps if the technology is validated through major agreements or an acquisition. For 100 kroner to be justifiable, one or more of these things would probably have to happen: * a large licensing agreement with a global pharmaceutical company, * convincing clinical results, * or an acquisition at a high premium. It is therefore a high-risk/high-upside scenario. Many investors hope for such outcomes, but there is no public analysis today that points to 100 kroner as a realistic price target. If you think 2–5 years into the future, 100 kroner is not impossible if the technology becomes a commercial success. But the probability is significantly lower than for more moderate outcomes, and the risk of the project not succeeding is also high.
He might as well take a trip to his mother-in-law in Asia, over to another time zone 😅- ·2 t sittenHarder fight against 7.50 kr every day, the more the stock gets suppressed, I unfortunately believe everyone must understand that the company must decide for itself.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
77 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·23 min sittenThese are incredibly exciting opportunities. The Circio and Tcelltech collaboration aims to cure cancer that has entrenched itself with a single injection. When cancer has spread to multiple organs, we face a massive problem. To cure patients at this stage, we must program their immune cells to perform several demanding tasks simultaneously. Firstly, the immune cells must be able to track down tumors wherever they hide in the body. Secondly, they must be able to break down the hard, physical connective tissue that solid tumors build around themselves. And thirdly, they must be able to survive the toxic environment inside the tumor, which normally deactivates the body's own defenses. To program immune cells to do all this, we must introduce large amounts of genetic code into them. And here we hit a wall with today's technology: The standard is to use viruses to deliver the genes. But viruses are small. They have strict physical limitations and simply do not have room for the amount of genetic code required to tackle disseminated, solid cancer. This is what the collaboration between Circio and Tcelltech is now solving, so that treatment can occur directly inside the patient's body. Room for everything that is needed The solution starts with Tcelltech's technology, NanoSMAR. Since this is a synthetic DNA carrier that does not use viruses, it has extreme loading capacity. It removes the space problem. With NanoSMAR, researchers can package the entire genetic recipe in one and the same delivery: Both the instructions for tracking the cancer, the enzymes for breaking down the tumor's outer barriers, and the genes that keep the immune cell active. The treatment lasts until the job is done Once all these genes have been safely delivered into the cell, the next problem arises: Removing disseminated cancer takes time. Common gene recipes are quickly broken down in the body, and then the treatment burns out before all cancer cells are removed. This is where Circio's technology, circVec, comes in. They use circular RNA. Because the RNA is shaped like a closed ring without ends, the body's enzymes cannot break it down. This means that the immune cells continue to produce the necessary substances for several months. What this means in practice In short: NanoSMAR provides the space we need to deliver complex instructions, and circVec ensures that the instructions work for a long time. This gives us a concrete tool to give the patient a single injection. Subsequently, the body's own, upgraded immune cells will systematically hunt down and break down the cancer cells over several months, until the disease is gone. This is the technical foundation required to actually cure forms of cancer that are currently considered incurable.
- ·57 min sittenCompletely without news from Circio, one must well say that the alpine landscape of a graph (1d) we see above us, represents all those who try to earn some kroner on ups and downs. After a short year of trading on the stock exchange, what scares me is how easy it must be for a group of, for example, 4 people with 30 000 shares each, to influence the price. Concerted purchases start with many small and medium-sized positions, likewise sales. but there are surely control functions.....Well, there's no volume anyway. People are waiting for data. The big investors with the money, who are not in yet, are doing the same.
- ·1 t sittenHave learned one thing today. DO NOT WAKE @vidfar who is sleeping!!
- ·1 t sittenThe reason is: * Circio Holding is still a biotech company without established commercial earnings. Its value largely depends on research, partnerships, and potential licensing agreements. * The freshest independent analysis I find has a base case of around 5.9 kroner per share, even after strong research results and new financing. * At the same time, biotech is known for large price jumps if the technology is validated through major agreements or an acquisition. For 100 kroner to be justifiable, one or more of these things would probably have to happen: * a large licensing agreement with a global pharmaceutical company, * convincing clinical results, * or an acquisition at a high premium. It is therefore a high-risk/high-upside scenario. Many investors hope for such outcomes, but there is no public analysis today that points to 100 kroner as a realistic price target. If you think 2–5 years into the future, 100 kroner is not impossible if the technology becomes a commercial success. But the probability is significantly lower than for more moderate outcomes, and the risk of the project not succeeding is also high.He might as well take a trip to his mother-in-law in Asia, over to another time zone 😅
- ·2 t sittenHarder fight against 7.50 kr every day, the more the stock gets suppressed, I unfortunately believe everyone must understand that the company must decide for itself.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
77 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·23 min sittenThese are incredibly exciting opportunities. The Circio and Tcelltech collaboration aims to cure cancer that has entrenched itself with a single injection. When cancer has spread to multiple organs, we face a massive problem. To cure patients at this stage, we must program their immune cells to perform several demanding tasks simultaneously. Firstly, the immune cells must be able to track down tumors wherever they hide in the body. Secondly, they must be able to break down the hard, physical connective tissue that solid tumors build around themselves. And thirdly, they must be able to survive the toxic environment inside the tumor, which normally deactivates the body's own defenses. To program immune cells to do all this, we must introduce large amounts of genetic code into them. And here we hit a wall with today's technology: The standard is to use viruses to deliver the genes. But viruses are small. They have strict physical limitations and simply do not have room for the amount of genetic code required to tackle disseminated, solid cancer. This is what the collaboration between Circio and Tcelltech is now solving, so that treatment can occur directly inside the patient's body. Room for everything that is needed The solution starts with Tcelltech's technology, NanoSMAR. Since this is a synthetic DNA carrier that does not use viruses, it has extreme loading capacity. It removes the space problem. With NanoSMAR, researchers can package the entire genetic recipe in one and the same delivery: Both the instructions for tracking the cancer, the enzymes for breaking down the tumor's outer barriers, and the genes that keep the immune cell active. The treatment lasts until the job is done Once all these genes have been safely delivered into the cell, the next problem arises: Removing disseminated cancer takes time. Common gene recipes are quickly broken down in the body, and then the treatment burns out before all cancer cells are removed. This is where Circio's technology, circVec, comes in. They use circular RNA. Because the RNA is shaped like a closed ring without ends, the body's enzymes cannot break it down. This means that the immune cells continue to produce the necessary substances for several months. What this means in practice In short: NanoSMAR provides the space we need to deliver complex instructions, and circVec ensures that the instructions work for a long time. This gives us a concrete tool to give the patient a single injection. Subsequently, the body's own, upgraded immune cells will systematically hunt down and break down the cancer cells over several months, until the disease is gone. This is the technical foundation required to actually cure forms of cancer that are currently considered incurable.
- ·57 min sittenCompletely without news from Circio, one must well say that the alpine landscape of a graph (1d) we see above us, represents all those who try to earn some kroner on ups and downs. After a short year of trading on the stock exchange, what scares me is how easy it must be for a group of, for example, 4 people with 30 000 shares each, to influence the price. Concerted purchases start with many small and medium-sized positions, likewise sales. but there are surely control functions.....Well, there's no volume anyway. People are waiting for data. The big investors with the money, who are not in yet, are doing the same.
- ·1 t sittenHave learned one thing today. DO NOT WAKE @vidfar who is sleeping!!
- ·1 t sittenThe reason is: * Circio Holding is still a biotech company without established commercial earnings. Its value largely depends on research, partnerships, and potential licensing agreements. * The freshest independent analysis I find has a base case of around 5.9 kroner per share, even after strong research results and new financing. * At the same time, biotech is known for large price jumps if the technology is validated through major agreements or an acquisition. For 100 kroner to be justifiable, one or more of these things would probably have to happen: * a large licensing agreement with a global pharmaceutical company, * convincing clinical results, * or an acquisition at a high premium. It is therefore a high-risk/high-upside scenario. Many investors hope for such outcomes, but there is no public analysis today that points to 100 kroner as a realistic price target. If you think 2–5 years into the future, 100 kroner is not impossible if the technology becomes a commercial success. But the probability is significantly lower than for more moderate outcomes, and the risk of the project not succeeding is also high.He might as well take a trip to his mother-in-law in Asia, over to another time zone 😅
- ·2 t sittenHarder fight against 7.50 kr every day, the more the stock gets suppressed, I unfortunately believe everyone must understand that the company must decide for itself.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt